这篇文章介绍了一项针对HER2阳性乳腺癌患者使用新型抗体药物偶联物（ADC）SHR-A1811进行新辅助治疗的转化研究。研究利用多组学数据，包括基因组学、转录组学和先进的空间分析技术，旨在识别预测治疗反应的生物标志物。研究发现，治疗效果与肿瘤微环境（TME）的特征，特别是细胞毒性T细胞的数量和分布，以及HER2强阳性肿瘤细胞的空间聚集模式有关，这些关联在激素受体（HR）阴性和阳性亚组中表现出不同的机制。最后，研究人员开发了一个基于人工智能的预测模型，结合临床病理特征和数字病理图像，用于预测SHR-A1811和其他新型ADC的疗效。References: Ma D, Dai L J, Wu X R, et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer[J]. Cancer Cell, 2025, 43(6): 1061-1075. e7.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Trump $82 Million Bond Spree, Brazil Tariffs 'Too High,' More
16 Nov 2025
Bloomberg News Now
Ex-Fed Gov Resigned After Rules Violations, Trump Buys $82 Mil of Bonds, More
16 Nov 2025
Bloomberg News Now
THIS TRUMP INTERVIEW WAS INSANE!
16 Nov 2025
HasanAbi
Epstein Emails and Trump's Alleged Involvement
15 Nov 2025
Conspiracy Theories Exploring The Unseen
New Epstein Emails Directly Implicate Trump - H3 Show #211
15 Nov 2025
H3 Podcast
Trump Humiliates Himself on FOX as They Call Him Out
15 Nov 2025
IHIP News